BMP4-Induced Suppression of Breast Cancer Metastasis Is Associated with Inhibition of Cholesterol Biosynthesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bone morphogenetic protein 4 (BMP4) is a known inhibitor of breast cancer metastasis.
• High BMP4 protein levels correlate with favorable patient outcomes in breast cancer.
• Understanding the molecular mechanisms of BMP4's anti-metastatic effects is crucial.

Purpose of the Study:

• To elucidate the mechanisms by which BMP4 suppresses breast cancer metastasis.
• To investigate the role of cholesterol biosynthesis in BMP4-mediated anti-metastatic activity.
• To evaluate BMP4 as a potential predictive biomarker for statin therapy response.

Main Methods:

• Analysis of breast cancer xenografts with and without enforced BMP4 expression.
• Transcriptomic analysis of cancer cells from primary tumors.
• Phosphoproteomic analysis of cancer cells treated with recombinant BMP4.
• Treatment of xenografts with cholesterol-lowering statins.
• Analysis of patient cohorts with primary breast cancers.

Main Results:

• BMP4 was found to inhibit cholesterol biosynthesis, downregulating key genes in the pathway.
• Statin treatment in mice with low-BMP4 xenografts partially replicated BMP4's anti-metastatic effects.
• Patients with low BMP4 levels in their tumors showed reduced relapse rates when on statin therapy.

Conclusions:

• BMP4 suppresses breast cancer metastasis, partly by inhibiting cholesterol biosynthesis.
• BMP4 may serve as a predictive biomarker for identifying breast cancer patients who would benefit from statin therapy.
• Combined BMP4 and statin therapy could be a potential strategy for reducing breast cancer recurrence.